Incyte expanded its AI strategy by partnering with Edison Scientific to embed Kosmos across drug discovery and development workflows. Edison’s AI scientist Kosmos will be trained on Incyte’s translational and clinical data to generate predictive models of therapeutic performance, with initial focus on high-impact use cases. Incyte’s move reflects a broader shift toward using AI not only for analysis but also for continuously learning from ongoing data streams to guide experimental design. The collaboration is designed to improve quality and consistency of decisions that feed into candidate selection and clinical development. For drug developers, the key operational change is data integration: Kosmos will sit within Incyte’s internal R&D cycle rather than operate as an external analytics tool.